Canadian market for ProStrakan

ProStrakan, the Borders-based drugs developer, yesterday revealed its cancer pain-killing medicine Abstral had gone on sale in Canada.

The announcement is the first since Galashiels-based ProStrakan was bought for 300 million in February by Japanese peer Kyowa Hakko Kirin.

The Scottish firm out-licensed the Canadian rights to Paladin in December 2008 and Abstral was granted Canadian regulatory approval in February.

The medicine is already being sold in Europe and was launched in the United States earlier this year.